Browse the corpus

REFERENCES American Diabetes Association, “Standards of Medical Care in Diabetes Mellitus -- 2012,” Diabetes Care , 2012, 35(Suppl ):11-63. [PubMed 22187469 ] Anderson JL, Adams CD, Antman EM, et al, “ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,” J Am Coll Cardiol , 2007, 50(7):e1-e157. [PubMed 17692738 ] Antman EM, Anbe SC, Alpert JS, et al, “ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),” Circulation , 2004, 110(5):588-636. Available at file://www.circulationaha.org/cgi/content/full/110/5/588 [PubMed 15289388 ] Antman EM, Hand M, Armstrong PW, et al, “2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” J Am Coll Cardiol , 2008, 51(2):210-49. [PubMed 18191746 ] Chobanian AV, Bakris GL, Black HR, et al, “The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,” JAMA , 2003, 289(19):2560-71. [PubMed 12748199 ] Cohn JN and Tognoni G, “Valsartan Heart Failure Trial Investigators. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure,” N Engl J Med , 2001, 345(23):1667-75. [PubMed 11759645 ] Conlin P, Moore T, Swartz S, et al, “Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,” Hypertension , 2000, 36(3):461-5. [PubMed 10988282 ]

Cohn JN and Tognoni G, “Valsartan Heart Failure Trial Investigators. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure,” N Engl J Med , 2001, 345(23):1667-75. [PubMed 11759645 ] Conlin P, Moore T, Swartz S, et al, “Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,” Hypertension , 2000, 36(3):461-5. [PubMed 10988282 ] Dahlof B, Devereux RB, Kjeldsen SE, et al, “Cardiovascular Morbidity and Mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol,” Lancet , 2002, 359(9311):995-1003. [PubMed 11937178 ] Dickstein K and Kjekshus J, “Effects of Losartan and Captopril on Mortality and Morbidity in High-Risk Patients After Acute Myocardial Infarction: The OPTIMAAL Randomised Trial. Optimal Trial in Myocardial Infarction With Angiotensin II Antagonist Losartan,” Lancet , 2002, 360(9335):752-60. [PubMed 12241832 ] Epstein BJ and Gums JG, “Angiotensin Receptor Blockers Versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations,” Ann Pharmacother , 2005, 39(3):470-80. [PubMed 15701766 ] Fihn SD, Gardin JM, Abrams J, et al, “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,” Circulation , 2012, 126(25):3097-137. [PubMed 23166211 ] Granger CB, McMurray JJ, Yusuf S, et al, “Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Alternative Trial,” Lancet , 2003, 362(9386):772-6. [PubMed 13678870 ] Hamroff G, Katz SD, Mancini D, et al, “Addition of Angiotensin II Receptor Blockade to Maximal Angiotensin-Converting Enzyme Inhibition Improves Exercise Capacity in Patients With Severe Congestive Heart Failure,” Circulation , 1999, 99(8):990-2. [PubMed 10051289 ]

Granger CB, McMurray JJ, Yusuf S, et al, “Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Alternative Trial,” Lancet , 2003, 362(9386):772-6. [PubMed 13678870 ] Hamroff G, Katz SD, Mancini D, et al, “Addition of Angiotensin II Receptor Blockade to Maximal Angiotensin-Converting Enzyme Inhibition Improves Exercise Capacity in Patients With Severe Congestive Heart Failure,” Circulation , 1999, 99(8):990-2. [PubMed 10051289 ] Hillis LD, Smith PK, Anderson JL, et al, “2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Circulation , 2011, 124(23):2610-42. [PubMed 22064600 ] Hunt SA, Abraham WT, Chin MH, et al, “2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,” CIrculation , 2009, 119(14):e391-479. [PubMed 19324966 ] “K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,” Am J Kidney Dis , 2002, 39(2 Suppl 2):1-246. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm Lindenfeld J, Albert NM, Boehmer JP, et al, “HFSA 2010 Comprehensive Heart Failure Practice Guideline,” J Card Fail , 2010, 16(6):e1-194. [PubMed 20610207 ] McInnes GT, O'Kane KP, Jonker J, et al, “The Efficacy and Tolerability of Candesartan Cilexetil in an Elderly Hypertensive Population,” J Hum Hypertens , 1997, 11(Suppl 2):75-80. [PubMed 9140794 ] McKelvie RS, Yusuf S, Pericak D, et al, “Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study: The RESOLVD Pilot Study Investigators,” Circulation , 1999, 100(10):1056-64. [PubMed 10477530 ]

McInnes GT, O'Kane KP, Jonker J, et al, “The Efficacy and Tolerability of Candesartan Cilexetil in an Elderly Hypertensive Population,” J Hum Hypertens , 1997, 11(Suppl 2):75-80. [PubMed 9140794 ] McKelvie RS, Yusuf S, Pericak D, et al, “Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study: The RESOLVD Pilot Study Investigators,” Circulation , 1999, 100(10):1056-64. [PubMed 10477530 ] McMurray JJ, Ostergren J, Swedberg K, et al, “Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Added Trial,” Lancet , 2003, 362(9386):767-71. [PubMed 13678869 ] Morsing P, Adler G, Brandt-Eliasson U, et al, “Mechanistic Differences of Various AT1-Receptor Blockers in Isolated Vessels of Different Origin,” Hypertension , 1999, 33(6):1406-13. [PubMed 10373224 ] Pfeffer MA, McMurray JJ, Velazquez EJ, et al, “Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,” N Engl J Med , 2004, 350(2):203. Pitt B, Poole-Wilson PA, Segal R, et al, “Effect of Losartan Compared With Captopril on Mortality in Patients With Symptomatic Heart Failure: Randomised Trial - The Losartan Heart Failure Survival Study ELITE II,” Lancet , 2000, 355(9215):1582-7. [PubMed 10821361 ] Reif M, White WB, Fagan TC, et al, “Effects of Candesartan Cilexetil in Patients With Systemic Hypertension. Candesartan Cilexetil Study Investigators,” Am J Cardiol , 1998, 82(8):961-5. [PubMed 9794352 ] Riegger GA, Bouzo H, Petr P, et al, “Improvement in Exercise Tolerance and Symptoms of Congestive Heart Failure During Treatment With Candesartan Cilexetil,” Circulation , 1999, 100(22):2224-30. [PubMed 10577995 ] Sipahi I, Debanne SM, Rowland DY, et al, “Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,” Lancet Oncol , 2010, 11(7):627-36. [PubMed 20542468 ] Smith SC Jr, Benjamin EJ, Bonow RO, et al, “AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,” Circulation , 2011, 124(22):2458-73. [PubMed 22052934 ]

Smith SC Jr, Benjamin EJ, Bonow RO, et al, “AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,” Circulation , 2011, 124(22):2458-73. [PubMed 22052934 ] Swedberg K, Pfeffer M, Granger C, et al, “Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and Design. Charm-Programme Investigators,” J Card Fail , 1999, 5(3):276-82. [PubMed 10496201 ] Yusuf S, Pfeffer MA, Swedberg K, et al, “Effects of Candesartan in Patients With Chronic Heart Failure and Preserved Left-Ventricular Ejection Fraction: The CHARM-Preserved Trial,” Lancet , 2003, 362(9386):777-81. [PubMed 13678871 ] Topic 8670 Version 48.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.4 - C21.36 Licensed to: Southeast Alabama Med Ctr | Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]